VEGFA and neoplasm: Concerning moDCs, they can loss its anti-tumour activity and may contribute to an immunosuppressive environment at the tumour site in lung and CRC patients [165] and in human SCC microenvironment (Table 1) wherein TGF-β, IL-10 and VEGF-A can suppress DC function resulting in impairment of T cell activation [166].